Table 2.
Univariate Analysis of PFS and OS
| Clinical Variable | OS | PFS | ||
|---|---|---|---|---|
| Median OS (95% CI), Months | P-value | Median PFS (95% CI), Months | P-value | |
| Sex | 0.605 | 0.672 | ||
| Male (n=45) | 41.8 (22.151–61.449) | 18.200 (12.930–23.470) | ||
| Female (n=69) | 31.2 (25.095–37.305) | 15.300 (10.455–20.145) | ||
| Smoke history | 0.959 | 0.923 | ||
| Never smoke (n=77) | 33.267 (25.136–41.397) | 15.700 (9.918–21.482) | ||
| Current and ex-smoker (n=37) | 41.800 (23.908–59.692) | 18.200 (10.590–25.810) | ||
| Histology | 0.359 | 0.179 | ||
| Adenocarcinoma (n=112) | NE | NE | ||
| Adenosquamous or NOS (n=2) | NE | NE | ||
| Performance status | <0.001 | <0.001 | ||
| 0–1 (n=81) | 42.633 (35.318–49.949) | 26.300 (17.792–34.808) | ||
| 2–4 (n=33) | 15.500 (11.964–19.036) | 8.400 (7.669–9.131) | ||
| EGFR | 0.790 | 0.736 | ||
| Exon 19 (n=55) | 33.433 (20.466–46.401) | 18.400 (11.510–25.290) | ||
| Exon 21 (n=53) | 33.267 (25.038–41.495) | 14.800 (9.793–19.807) | ||
| Other exon (18 or 20) (n=6) | 33.567 (0.000–81.652) | 6.470 (5.489–7.451) | ||
| Weight loss on initial diagnosis | 0.434 | 0.275 | ||
| No (n=76) | 35.400 (31.343–39.457) | 18.200 (12.340–24.060) | ||
| Yes (n=38) | 25.867 (18.303–33.431) | 12.600 (7.314–17.886) | ||
| Post operation recurrence | 0.224 | 0.223 | ||
| No (n=111) | 33.433 (26.776–40.091) | 15.300 (10.657–19.943) | ||
| Yes (n=3) | NE | NE | ||
| Distant metastasis on initial diagnosis | 0.003 | 0.015 | ||
| No (n=30) | 43.533 (37.836–49.231) | 28.300 (11.166–45.434) | ||
| Yes (n=84) | 28.300 (19.412–37.188) | 12.600 (7.857–17.343) | ||
| Pleural metastasis on initial diagnosis | 0.083 | 0.183 | ||
| No (n=75) | 35.333 (26.573–44.094) | 16.200 (9.854–22.546) | ||
| Yes (n=39) | 28.300 (12.324–44.276) | 13.600 (1.366–25.834) | ||
| Brain metastasis | 0.007 | 0.070 | ||
| No (n=75) | 39.933 (32.067–47.800) | 18.200 (7.504–28.896) | ||
| Yes (n=39) | 25.867 (16.349–35.384) | 12.100 (5.173–19.027) | ||
| PD-L1 | 0.769 | 0.738 | ||
| <1% (n=54) | 33.567 (24.399–42.734) | 13.600 (6.822–20.378) | ||
| 1–49% (n=50) | 30.133 (19.450–40.817) | 18.400 (8.491–28.309) | ||
| ≥50% (n=10) | 48.567 (24.273–72.860) | 15.700 (14.530–16.870) | ||
| EGFR-TKI | 0.127 | 0.011 | ||
| Gefitinib (n=42) | 31.200 (23.822–38.578) | 12.100 (8.726–15.474) | ||
| Erlotinib (n=36) | 33.567 (21.954–45.180) | 15.200 (10.993–19.407) | ||
| Afatinib (n=36) | 58.900 (25.029–92.771) | 28.300 (15.558–41.042) | ||
| EGFR-TKI + anti-angiogenesis | 0.705 | 0.291 | ||
| No (n=101) | 33.433 (25.598–41.269) | 14.800 (10.053–19.547) | ||
| Yes (n=13) | 42.733 (NE) | 27.700 (NE) |
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; OS, overall survival; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; NE, not estimable.